Kaken Pharmaceutical Co., Ltd.（KKPCF）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · KKPCF · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2026-03	2025-03	2024-03	2023-03	2022-03
Revenue
Revenue	$77.35B	$94.03B	$72.04B	$72.98B	$76.03B
Cost of Revenue	$37.87B	$35.50B	$33.51B	$33.43B	$34.46B
Gross Profit	$39.49B	$58.53B	$38.54B	$39.56B	$41.58B
Gross Margin %(computed)	51.05%	62.24%	53.49%	54.20%	54.68%
Operating Expenses
R&D Expenses	$20.71B	$18.73B	$12.54B	$15.79B	$8.42B
G&A Expenses	$0.00B	$0.00B	$0.03B	$0.00B	$0.00B
Total Operating Expenses	$40.39B	$37.50B	$29.03B	$31.55B	$24.51B
Operating Income	($0.90B)	$21.03B	$9.51B	$8.00B	$17.06B
Operating Margin %(computed)	-1.17%	22.37%	13.20%	10.96%	22.44%
Interest Income	$0.28B	$0.08B	$0.01B	$0.01B	$0.01B
Interest Expense	$0.05B	$0.03B	$0.02B	$0.02B	$0.02B
Income Before Tax	$2.33B	$19.43B	$9.80B	$6.82B	$13.88B
Income Tax Expense	$0.17B	$5.49B	$1.77B	$1.38B	$4.34B
Net Income	$2.16B	$13.95B	$8.03B	$5.44B	$9.55B
Net Margin %(computed)	2.79%	14.83%	11.14%	7.45%	12.56%
Per Share & EBITDA
EPS (Basic)	$57.52	$365.42	$212.66	$144.79	$251.44
Wtd Avg Shares	0.04B	0.04B	0.04B	0.04B	0.04B
EBITDA	$2.44B	$22.02B	$12.57B	$9.40B	$16.38B
EBITDA Margin %(computed)	3.16%	23.41%	17.44%	12.88%	21.55%